[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595433":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":24,"responsibleParty":44,"collaborators":48,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":18,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":26,"whyStopped":18,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Polypill","EXPERIMENTAL","The polypill combines DAPT and a high intensity statin: (a) aspirin 81 mg, (b) rosuvastatin (40 or 10 mg) and (c) prasugrel 10 mg or clopidogrel 75 mg.",[13],"Combination Product: Polypill",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual care","NO_INTERVENTION","Participants in the usual care arm will be prescribed DAPT and statins as standard therapy in individual pills.",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"COMBINATION_PRODUCT","The polypill is an inert capsule designed to combine multiple individual medications into a convenient, once-daily pill. In this case it will include DAPT and a statin.",[9],[25],{"facility":5,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Dallas","Texas","75209","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-96.80667,32.78306,{"lat":36,"lon":35},[39],{"name":40,"role":41,"phone":42,"phoneExt":18,"email":43},"Ambarish Pandey, MD","CONTACT","214-645-9868","ambarish.pandey@utsouthwestern.edu",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Ambarish Pandey","Associate Professor",[49],{"name":50,"class":51},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100595433","phase-2-a-polypill-for-acute-coronary-syndrome-100595433",false,"NCT07032389","A Polypill for Acute Coronary Syndrome","Polypill Strategy for the Treatment of Patients After Acute Coronary Syndromes - A Multicenter Randomized Controlled Trial","PolyACS","Inclusion Criteria:\n\n* Age ≥ 18\n* Hospitalization for acute coronary syndrome with percutaneous coronary intervention\n* Discharged on aspirin, prasugrel or clopidogrel, and a high-intensity statin\n\nExclusion Criteria:\n\n* Current need for systemic anticoagulation\n* Contraindication to receive any components of the polypill\n* History of allergic reaction or intolerance to aspirin, prasugrel or clopidogrel, or rosuvastatin\n* Comorbidities that might be expected to limit lifespan within the 12-month study period\n* Increased risk of bleeding or planned urgent surgery that would necessitate use of DAPT for \\\u003C 12 months\n* Inability to provide written informed consent\n* Pregnancy","ALL","18 Years",{"count":63,"type":64},1000,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","The current study aims to investigate whether combining the standard medications prescribed after acute coronary syndrome (ACS)-aspirin, P2Y12 inhibitors, and statins-into a single polypill can improve outcomes following an ACS event. Although these therapies are effective, gaps in adherence and uptake significantly contribute to risk or adverse events in the post-ACS period. This study is designed as a pragmatic, multi-center, randomized trial to assess the feasibility and effectiveness of a polypill-based strategy for treatment of ACS.",[70],"Acute Coronary Syndrome",[70,9,72],"Adherence","2026-01-16",{"date":75,"type":76},"2026-01-20","ACTUAL",{"date":78,"type":76},"2025-12-05",{"date":80,"type":64},"2029-08-01",{"name":5,"class":6},1]